Celldex Therapeutics, Inc.
CLDX
$32.51
$0.511.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -46.27% | -72.68% | -59.17% | -57.92% | -63.97% |
| Total Depreciation and Amortization | -1.50% | -0.37% | 4.83% | 9.54% | 11.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.95% | 25.01% | 47.21% | 158.79% | 80.99% |
| Change in Net Operating Assets | 151.17% | 15.70% | 150.81% | 49.65% | 32.04% |
| Cash from Operations | -20.63% | -96.88% | 12.12% | -50.05% | -33.80% |
| Capital Expenditure | -518.49% | -69.44% | 19.27% | -165.69% | 22.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.68% | 128.63% | 26.88% | 208.89% | 113.72% |
| Cash from Investing | 67.91% | 130.49% | 27.41% | 206.69% | 113.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 61.88% | 249.48% | -37.53% | -98.30% | -99.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 61.88% | 249.48% | -37.53% | -98.30% | -99.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.12% | 10.90% | 304.94% | 108.17% | -113.98% |